S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Novavax Stock Forecast, Price & News

-1.10 (-0.60%)
(As of 12/8/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
4.56 million shs
Average Volume
4.69 million shs
Market Capitalization
$13.74 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

Novavax logo

About Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.


Novavax (NASDAQ:NVAX) Shares Gap Down to $182.85
December 8, 2021 |  americanbankingnews.com
Novavax (NASDAQ:NVAX) Shares Up 11.9%
December 7, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$475.60 million
Book Value
$6.10 per share


Net Income
$-418.26 million
Pretax Margin




Free Float
Market Cap
$13.74 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.13 out of 5 stars

Medical Sector

479th out of 1,394 stocks

Biological Products, Except Diagnostic Industry

77th out of 202 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Novavax (NASDAQ:NVAX) Frequently Asked Questions

Is Novavax a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax
or view top-rated stocks.

How has Novavax's stock been impacted by COVID-19?

Novavax's stock was trading at $10.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVAX stock has increased by 1,629.3% and is now trading at $181.75.
View which stocks have been most impacted by COVID-19

Are investors shorting Novavax?

Novavax saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 8,240,000 shares, an increase of 33.8% from the October 14th total of 6,160,000 shares. Based on an average daily volume of 5,400,000 shares, the short-interest ratio is presently 1.5 days. Currently, 11.2% of the shares of the stock are sold short.
View Novavax's Short Interest

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Novavax

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.04) by $0.27. The biopharmaceutical company earned $178.80 million during the quarter, compared to analysts' expectations of $347.34 million. Novavax had a negative net margin of 89.31% and a negative trailing twelve-month return on equity of 149.66%. The business's revenue for the quarter was up 13.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($3.21) EPS.
View Novavax's earnings history

When did Novavax's stock split? How did Novavax's stock split work?

Shares of Novavax reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

6 brokerages have issued 12-month price targets for Novavax's stock. Their forecasts range from $161.00 to $294.00. On average, they expect Novavax's share price to reach $249.60 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts' price targets for Novavax
or view top-rated stocks among Wall Street analysts.

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Stanley C. Erck, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Richard Crowley, Chief Operating Officer & Executive Vice President
  • James Patrick Kelly, Chief Financial Officer, Treasurer & Executive VP
  • Gregory M. Glenn, President-Research & Development (LinkedIn Profile)
  • Filip Dubovsky, Chief Medical Officer & Executive Vice President

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (2.77%), Capital World Investors (1.96%), Citadel Advisors LLC (0.00%), Franklin Resources Inc. (1.42%), Geode Capital Management LLC (1.27%) and Jane Street Group LLC (0.00%). Company insiders that own Novavax stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax

Which institutional investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Wellington Management Group LLP, PEAK6 Investments LLC, Schroder Investment Management Group, Lombard Odier Asset Management Switzerland SA, Balyasny Asset Management LLC, Balyasny Asset Management LLC, and Franklin Resources Inc.. Company insiders that have sold Novavax company stock in the last year include David M Mott, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax
or view top insider-selling stocks.

Which institutional investors are buying Novavax stock?

NVAX stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, IMC Chicago LLC, Lord Abbett & CO. LLC, Citadel Advisors LLC, Connor Clark & Lunn Investment Management Ltd., Allianz Asset Management GmbH, Geode Capital Management LLC, and Worldquant Millennium Advisors LLC. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax
or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $181.75.

How much money does Novavax make?

Novavax has a market capitalization of $13.74 billion and generates $475.60 million in revenue each year. The biopharmaceutical company earns $-418.26 million in net income (profit) each year or ($14.81) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 375 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

Where are Novavax's headquarters?

Novavax is headquartered at 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at [email protected], or via fax at 240-268-2100.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.